Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omr-IgG-am IGIV in Primary Immune Deficiency Diseases
NCT00468273Phase 3Completed
- Sponsor
- FFF Enterprises
- Start
- Nov 2006
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of Omr-IgG-am in primary immunodeficiency disease (PID), sponsored by FFF Enterprises. Started Nov 2006; status: completed.
02
Drugs
Omr-IgG-am
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT00468273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468273.